Global Vaccines is a new not-for-profit company that acquires state-of-the-art vaccine technologies and applies them to diseases of poorer countries. We develop platform vaccine technologies that can be applied to a broad spectrum of disease targets of both developed and undeveloped countries. Global will apply these technologies to diseases of undeveloped countries and also may sublicense these technologies to commercial companies for use in the more profitable markets of developed countries. By sublicensing these value added technologies to the commercial pharmaceutical industry, Global Vaccines provides new technologies to the commercial market that are more fully proven and therefore less financially risky. 
 We currently hold exclusive worldwide license to two technologies and are actively seeking several additional licenses.  The Global Vaccines licensing strategy provides the inventors (usually academic researchers and their institutions) with both increased downstream revenues and collaborative research grants.  These benefits to the inventors and patent owners have enabled us to secure licenses from academic institutions for very low fees. As with a for-profit company, Global Vaccines obtains exclusive, worldwide rights in return for payment of an initial licensing fee and assumption of patent expenses.  Due to the immature nature of these technologies the license fees are extremely low and patent costs are minimal because only a provisional patent has been filed.  In contrast to most commercial concerns however, Global Vaccines and the university remain partners through collaborative grant funding during the development of the technology through proof-of-concept. By advancing our technologies to proof-of-concept, the value of the technology is far greater than at the time of the original license.  The technologies developed by Global have very broad applications outside of the vaccine field and therefore hold great value to the commercial biotechnology market as a whole. We will utilize the sublicense fees to fund the continual development of the company’s technology platform and the development of vaccines for the developing world.  In the end, everyone wins with the Global Vaccines solution: people in poor countries recieve much needed vaccines,  researchers are able to see their inventions applied to benefit global health, and the phamaceutical industry has access to improved technologies for use in their commercial markets.

Download an Global Vaccines executive summary here